Human CD55/DAF Biotinylated Antibody Summary
Asp35-Ser353
Accession # P08174
Applications
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
Scientific Data
View Larger
CD55/DAF in Human PBMCs. CD55/DAF was detected in immersion fixed human peripheral blood mononuclear cells (PBMCs) using Goat Anti-Human CD55/DAF Biotinylated Antigen Affinity-purified Polyclonal Antibody (Catalog # BAF2009) at 10 µg/mL for 3 hours at room temperature. Cells were stained using the NorthernLights™ 557-conjugated Streptavidin (yellow; Catalog # NL999) and counterstained with DAPI (blue). View our protocol for Fluorescent ICC Staining of Non-adherent Cells.
View Larger
CD55/DAF in HeLa Human Cell Line. CD55/DAF was detected in immersion fixed HeLa human cervical epithelial carcinoma cell line (positive staining) and SH‑SY5Y human neuroblastoma cell line (negative staining) using Goat Anti-Human CD55/DAF Biotinylated Antigen Affinity-purified Polyclonal Antibody (Catalog # BAF2009) at 5 µg/mL for 3 hours at room temperature. Cells were stained using the NorthernLights™ 557-conjugated Streptavidin (red; NL999) and counterstained with DAPI (blue). Specific staining was localized to cytoplasm. Staining was performed using our protocol for Fluorescent ICC Staining of Non-adherent Cells.
Reconstitution Calculator
Preparation and Storage
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: CD55/DAF
CD55, also known as DAF or decay-accelerating factor, is a 70‑75 kDa member of the RCA family of proteins. Human RCA (regulators of complement/C’ activation) proteins are products of chromosome 1 genes that are ubiquitously expressed on cells exposed to plasma complement proteins (1‑4). A hallmark of RCA proteins is the presence of four to 30 SCRs (short consensus repeats; also called CCPs for C’ control protein modules) in their plasma-exposed regions. SCRs are characterized by a 60‑65 amino acid (aa) module that contains a highly conserved Trp residue and two internal disulfide bonds that create a beta -barrel structure (1). Human CD55 is synthesized as a 381 aa precursor that contains a 34 aa signal sequence, a 319 aa mature region and a 28 aa C-terminal prosegment (5, 6). The mature region contains four SCR modules and a C-terminal O-glycosylated extension (7). Following cleavage of the prosegment, a serine is exposed that serves as an anchor for a GPI-linkage (8). Multiple polymorphisms are found in the molecule. Alternate splicing also exists. One form that may not be translated shows an intron insertion in the prosegment, resulting in a 79 aa substitution for the standard C-terminal 20 aas of the prosegment (6). Another form generates a truncated 199 aa precursor that cannot be membrane-bound and may not be secreted (9). Mature CD55 is 53% and 84% aa identical to mouse and monkey CD55, respectively. CD55 is known to bind CD97 via the first SCR (4). It also binds physiologically-generated C3 convertases with its second and third SCRs (7, 10). Binding results in an accelerated “decay”, or dissociation of active C3 convertases, thus blocking the development of C’ attack complexes on nonforeign cells (1, 2). Finally, viruses and bacteria are also known to utilize multiple SCR sites for infection (4).
- Herbert, A. et al. (2002) Biochem. Soc. Trans. 30:990.
- Miwa, T. and W-C. Song (2001) Int. Immunopharmacol. 1:445.
- Hourcade, D. et al. (2000) Immunopharmacology 49:103.
- Lea, S. (2002) Biochem. Soc. Trans. 30:1014.
- Medof, M.E. et al. (1987) Proc. Natl. Acad. Sci. USA 84:2007.
- Caras, I.W. et al. (1987) Nature 325:545.
- Lukacik, P. et al. (2004) Proc. Natl. Acad. Sci. USA 101:1279.
- Moran, P. et al. (1991) J. Biol. Chem. 266:1250.
- Lublin, D.M. et al. (1994) Blood 84:1276.
- Williams, P. et al. (2003) J. Biol. Chem. 278:10691.
Product Datasheets
Citations for Human CD55/DAF Biotinylated Antibody
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
2
Citations: Showing 1 - 2
Filter your results:
Filter by:
-
Complement inhibition ameliorates blast-induced acute lung injury in rats: Potential role of complement in intracellular HMGB1-mediated inflammation
Authors: Y Li, Z Yang, M Chavko, B Liu, OA Aderemi, MO Simovic, MA Dubick, LC Cancio
PLoS ONE, 2018-08-22;13(8):e0202594.
Species: Rat
Sample Types: Whole Tissue
Applications: IHC-Fr -
Decay-accelerating factor attenuates remote ischemia-reperfusion-initiated organ damage.
Authors: Weeks C, Moratz C, Zacharia A, Stracener C, Egan R, Peckham R, Moore FD, Tsokos GC
Clin. Immunol., 2007-07-12;124(3):311-27.
Species: Mouse
Sample Types: Whole Tissue
Applications: IHC-Fr
FAQs
No product specific FAQs exist for this product, however you may
View all Antibody FAQsReviews for Human CD55/DAF Biotinylated Antibody
There are currently no reviews for this product. Be the first to review Human CD55/DAF Biotinylated Antibody and earn rewards!
Have you used Human CD55/DAF Biotinylated Antibody?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
